Sumary of Adjuvant atezolizumab extends DFS for broad range of patients with stage II-IIIA NSCLC:
- September 10, 2021 2 min read Source/Disclosures Published by: Source: Altorki NK, et al.
- Back to Healio Adjuvant atezolizumab improved DFS among patients with non-small cell lung cancer with nodal involvement, according to study results.
- Researchers — who observed the benefit across most disease stages, surgery types and chemotherapy regimens — presented the findings from the exploratory analysis of the IMpower010 trial during International Association for the Study of Lung Cancer World Conference on Lung Cancer.
- 8-14, 2021. “Surgical resection followed by adjuvant chemotherapy is the standard of care for patients with stage II to stage III NSCLC.
- The topline results of the interim analyses of the IMpower010 trial presented during the 2021 virtual ASCO meeting showed the trial met its primary endpoint of significant DFS in patients with PD-L1-expressing stage II to stage III NSCLC,” Nasser K. Altorki, MD, chief of thoracic surgery at Weill Cornell Medicine, said during a presentation.
- “For this current presentation, we have explored prior use of therapies — including surgery type — and their potential impact on DFS outcomes in patients receiving adjuvant atezolizumab [Tecentriq, Genentech] or best supportive care.
- ” As Healio previously reported, the IMpower010 trial enrolled 1,280 patients with stage IB to stage IIIA NSCLC and an ECOG performance status of 0 to 1 who underwent complete resection 4 to 12 weeks prior to enrollment.
- They then randomly assigned 1,005 patients (median age, 62 years;